Please login to the form below

Not currently logged in
Email:
Password:

Evoq Therapeutics

This page shows the latest Evoq Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Amgen plans acquisition of Rodeo Therapeutics

Amgen plans acquisition of Rodeo Therapeutics

Amgen has agreed to acquire US-based biopharma company Rodeo Therapeutics to strengthen its anti-inflammatory portfolio. ... Earlier this year, Amgen also entered into a licence and collaboration agreement with Evoq Therapeutics to develop novel drugs

Latest news

  • Amgen strikes $240m autoimmune deal with Evoq Therapeutics Amgen strikes $240m autoimmune deal with Evoq Therapeutics

    Companies will collaborate on novel drugs for autoimmune disorders. Amgen has entered into a license and collaboration agreement with Evoq Therapeutics worth over $240m, with the aim of developing novel drugs ... In a preclinical ‘gold-standard’

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...